Danske Bank A S Takes $133.05 Million Position in Gilead Sciences, Inc. $GILD

Danske Bank A S bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,198,637 shares of the biopharmaceutical company’s stock, valued at approximately $133,049,000. Danske Bank A S owned approximately 0.10% of Gilead Sciences as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC grew its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $215,000. Sivia Capital Partners LLC raised its position in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of Gilead Sciences by 9.0% during the 2nd quarter. Cetera Investment Advisers now owns 265,299 shares of the biopharmaceutical company’s stock worth $29,414,000 after acquiring an additional 21,966 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its holdings in shares of Gilead Sciences by 23.6% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 17,519 shares of the biopharmaceutical company’s stock worth $1,942,000 after acquiring an additional 3,347 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $144.40 on Wednesday. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company has a market cap of $179.26 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 1.90 and a beta of 0.37. The firm has a 50 day simple moving average of $141.62 and a 200 day simple moving average of $127.41.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 309,280 shares of company stock worth $44,068,850 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Arcellx / takeover-related coverage — reports note a Gilead-related takeover theme that drove a big one‑day move in a small biotech (Arcellx). M&A activity or strategic deals in cell therapy could be viewed positively for Gilead’s pipeline expansion and long-term growth prospects. This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
• Neutral Sentiment: Unusual options activity flagged by market scanners — Barchart/MSN highlighted Gilead among mega‑caps with unusual options flows, which can signal speculative interest or hedging by institutions but is ambiguous for directional bias. Monitor option volumes and put/call skew for confirmation. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider sale — Johanna Mercier sold 3,000 shares at an average $144.23 on Mar 16 (disclosed to the SEC). Insider selling can be interpreted negatively by investors even if part of routine diversification or pre-set plans. Insider Sale – Johanna Mercier (SEC Filing)
• Negative Sentiment: Insider sale — CFO Andrew D. Dickinson also sold 3,000 shares at an average $144.23 on Mar 16. A sale by the CFO can draw extra attention from investors and may weigh on sentiment in the near term. Insider Sale – Andrew D. Dickinson (SEC Filing)

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Cantor Fitzgerald upped their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. HSBC lifted their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Oppenheimer raised their price objective on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.